taking charge

Houston climatetech hub names new leader

Greentown Houston names Timmeko Moore Love as inaugural general manager. Photo courtesy of Greentown

Greentown Houston has a new leader at its helm.

The climatetech incubator, dual located in Houston and Somerville, Massachusetts, has named Timmeko Moore Love as Houston general manager and senior vice president of Greentown Labs. She'll lead Greentown Houston’s team and business operations, while growing the location's membership.

“We are thrilled to have Timmeko joining our leadership team,” says Jason Hanna, co-founder and interim CEO of Greentown Labs, in a news release. “Her wealth of experience will be instrumental in helping Greentown Houston maximize its impact through operational excellence, while inspiring and accelerating climate entrepreneurship from the energy capital of the world.”

Love has 20 years of experience in innovation management, per the news release, and was the first Black woman at a Fortune 500 to lead a venture capital program. In that role, which was at The Woodlands-based Entergy Corp., she was named to the 2020 Global Corporate Venturing Powerlist. Love also oversaw corporate ventures at Mayo Clinic and Best Buy Capital.

“Greentown Labs is committed to ensuring founders’ success and is an agent of action in the fight against climate change,” says Love in the release. “I am excited to continue my service to the Greater Houston climate innovation ecosystem through this esteemed platform, and partner internally and externally to evolve and expand our services and programs.”

Juliana Garaizar, who originally joined Greentown as launch director ahead of the Houston opening in 2021, previously oversaw the day-to-day operations of Greentown Houston. In January, she was promoted from vice president of innovation to chief development and investment officer. She shared with InnovationMap that Greentown was looking to hire its first Houston manager.

"Now that we are more than 80 members, we need more internal coordination," she told InnovationMap at the time. "Considering that the goal for Greentown is to grow to more locations, there's going to be more coordination and, I'd say, more autonomy for the Houston campus."

Greentown Labs is currently undergoing a search for its next CEO to succeed Emily Reichert, who stepped down in December.

------

This article originally ran on EnergyCapital.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted